Neovasc Stock Price, News & Analysis (NASDAQ:NVCN)

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVCN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCN, but not buy additional shares or sell existing shares.
View NVCN analyst ratings or view top-rated stocks.

Neovasc Inc. (NASDAQ:NVCN) released its earnings results on Tuesday, November, 9th. The medical equipment provider reported ($2.75) earnings per share for the quarter, missing analysts' consensus estimates of ($2.25) by $0.50. The medical equipment provider earned $0.70 million during the quarter, compared to analyst estimates of $1.20 million. Neovasc had a negative net margin of 1,082.92% and a negative trailing twelve-month return on equity of 127.25%. During the same quarter in the prior year, the firm earned ($12.75) earnings per share.

Shares of Neovasc reverse split on the morning of Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN), Heat Biologics (HTBX), Palatin Technologies (PTN), Amarin (AMRN).